BST:OMY

Stock Analysis Report

Executive Summary

Synairgen plc discovers and develops drugs for respiratory diseases.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Synairgen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OMY's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.9%

OMY

-0.7%

DE Biotechs

-0.6%

DE Market


1 Year Return

336.5%

OMY

-13.2%

DE Biotechs

-20.9%

DE Market

Return vs Industry: OMY exceeded the German Biotechs industry which returned -13.2% over the past year.

Return vs Market: OMY exceeded the German Market which returned -20.9% over the past year.


Shareholder returns

OMYIndustryMarket
7 Day-0.9%-0.7%-0.6%
30 Day152.3%-8.2%-18.6%
90 Day947.6%-21.0%-26.2%
1 Year336.5%336.5%-12.9%-13.2%-18.6%-20.9%
3 Year89.7%89.7%14.5%13.2%-19.0%-25.8%
5 Yearn/a-9.5%-11.8%-21.2%-31.8%

Price Volatility Vs. Market

How volatile is Synairgen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Synairgen undervalued compared to its fair value and its price relative to the market?

12.33x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OMY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OMY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OMY is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: OMY is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OMY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OMY is overvalued based on its PB Ratio (12.3x) compared to the DE Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Synairgen forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-80.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OMY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OMY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OMY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OMY is forecast to have no revenue next year.

High Growth Revenue: OMY is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OMY's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Synairgen performed over the past 5 years?

-17.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OMY is currently unprofitable.

Growing Profit Margin: OMY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OMY is unprofitable, and losses have increased over the past 5 years at a rate of -17.4% per year.

Accelerating Growth: Unable to compare OMY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OMY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: OMY has a negative Return on Equity (-82.64%), as it is currently unprofitable.


Next Steps

Financial Health

How is Synairgen's financial position?


Financial Position Analysis

Short Term Liabilities: OMY's short term assets (£4.9M) exceed its short term liabilities (£988.0K).

Long Term Liabilities: OMY has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: OMY is debt free.

Reducing Debt: OMY has not had any debt for past 5 years.


Balance Sheet

Inventory Level: OMY has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if OMY's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if OMY has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OMY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Synairgen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OMY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OMY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OMY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OMY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OMY's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.6yrs

Average management tenure


CEO

Richard Marsden (51yo)

10.58s

Tenure

UK£205,000

Compensation

Mr. Richard Marsden has been Chief Executive Officer of Synairgen Research Ltd since September 2009. Mr. Marsden has been Managing Director and Executive Director at Synairgen since June 2004 has been its  ...


CEO Compensation Analysis

Compensation vs Market: Richard's total compensation ($USD251.00K) is below average for companies of similar size in the German market ($USD434.26K).

Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Richard Marsden
CEO, MD & Executive Director10.58yrsUK£205.00k0.28% £188.1k
John Ward
Finance Director15.5yrsUK£162.00k0.31% £205.3k
Phillip Monk
Chairman of Scientific Advisory Boardno dataUK£148.00k0.21% £139.4k
Donna Davies
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Ratko Djukanovic
Co-Founder & Member of Scientific Advisory Boardno datano datano data

10.6yrs

Average Tenure

51yo

Average Age

Experienced Management: OMY's management team is seasoned and experienced (10.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Richard Marsden
CEO, MD & Executive Director10.58yrsUK£205.00k0.28% £188.1k
John Ward
Finance Director15.5yrsUK£162.00k0.31% £205.3k
Phillip Monk
Chairman of Scientific Advisory Boardno dataUK£148.00k0.21% £139.4k
Donna Davies
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Ratko Djukanovic
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Iain Peter Buchanan
Non-Executive Director & Member of Scientific Advisory Boardno dataUK£25.00k0.10% £68.3k
Simon James Shaw
Non-Executive Chairman16.83yrsUK£30.00k1.35% £892.5k
Stephen Holgate
Co-Founder16.83yrsUK£25.00k0.78% £519.7k
David Campbell
Non-Executive Director & Member of Scientific Advisory Boardno dataUK£25.00k0.27% £178.2k

16.3yrs

Average Tenure

57yo

Average Age

Experienced Board: OMY's board of directors are seasoned and experienced ( 16.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.1%.


Top Shareholders

Company Information

Synairgen plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Synairgen plc
  • Ticker: OMY
  • Exchange: BST
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£58.383m
  • Listing Market Cap: UK£66.259m
  • Shares outstanding: 120.38m
  • Website: https://www.synairgen.com

Number of Employees


Location

  • Synairgen plc
  • Mailpoint 810
  • Level F, South Block
  • Southampton
  • Hampshire
  • SO16 6YD
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SNGAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPOct 2004
OMYBST (Boerse-Stuttgart)YesOrdinary SharesDEEUROct 2004

Biography

Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Synairgen plc has research collaboration with Pharmaxis Ltd. to develop a LOXL2 inhibitor to the lysyl oxidase type 2 enzyme to treat IPF, a lung disease. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/04 04:24
End of Day Share Price2020/04/03 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.